Business

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

Financial Post · September 17, 2026 at 8:08 a.m.

TORONTO, Sept.

17, 2026 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target

More from Financial Post

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers

OpenAI expects US$70 billion in annualized revenue by end of 2026

More in Business

Globex Mining Enterprises Inc. Announces Normal Course Issuer Bid

Netflix is paying US$200 million for 2027 Women’s World Cup

ZenaTech Unveils Stacklens™, AI-Powered Smart Safety Glasses Built for Field Technicians and Industrial Workers

OpenAI expects US$70 billion in annualized revenue by end of 2026

ADAMnetworks Launches ClickNix, a Free Browser Extension to Stop ClickFix Attacks Before They Ever Reach the User

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment